CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

被引:630
|
作者
Wu, LJ
Paxton, WA
Kassam, N
Ruffing, N
Rottman, JB
Sullivan, N
Choe, H
Sodroski, J
Newman, W
Koup, RA
Mackay, CR
机构
[1] ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016
[2] HARVARD UNIV,SCH MED,DEPT PATHOL,DANA FABER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115
[3] HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115
关键词
D O I
10.1084/jem.185.9.1681
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chemokine receptors serve as coreceptors for HIV entry into CD4(+) cells. Their expression is thought to determine the tropism of viral strains for different cell types, and also to influence susceptibility to infection and rates of disease progression. Of the chemokine receptors, CCR5 is the most important for viral transmission, since CCR5 is the principal receptor for primary, macrophage-tropic viruses, and individuals homozygous for a defective CCR5 allele (Delta 32/Delta 32) are highly resistant to infection with HIV-1. In this study, CCR5-specific mAbs were generated using transfectants expressing high levels of CCR5. The specificity of these mAbs was confirmed using a broad panel of chemokine receptor transfectants, and by their non-reactivity with T cells from Delta 32/Delta 32 individuals. CCR5 showed a distinct pattern of expression, being abundant on long-term activated, IL-2-stimulated T cells, on a subset of effector/memory T cells in blood, and on tissue macrophages. A comparison of normal and CCR5 Delta 32 heterozygotes revealed markedly reduced expression of CCR5 on T cells from the heterozygotes. There was considerable individual to individual variability in the expression of CCR5 on blood T cells, that related to factors other than CCR5 genotype. Low expression of CCR5 correlated with the reduced infectability of T cells with macrophage-tropic HIV-1, in vitro. Anti-CCR5 mAbs inhibited the infection of PBMC by macrophage-tropic HIV-1 in vitro, but did not inhibit infection by T cell-tropic virus. Anti-CCR5 mAbs were poor inhibitors of chemokine binding, indicating that HIV-1 and ligands bind to separate, but overlapping regions of CCR5. These results illustrate many of the important biological features of CCR5, and demonstrate the feasibility of blocking macrophage-tropic HIV-1 entry into cells with an anti-CCR5 reagent.
引用
收藏
页码:1681 / 1691
页数:11
相关论文
共 50 条
  • [41] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [42] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131) : 866 - 870
  • [43] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [44] CCR5 genotype and the clinical course of HIV-1 infection
    Scribner, CL
    ANNALS OF INTERNAL MEDICINE, 1998, 128 (09) : 780 - 780
  • [45] The promise of CCR5 antagonists as new therapies for HIV-1
    Repik, Alexander
    Richards, Kathryn H.
    Clapham, Paul R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139
  • [46] CCR5, vertical transmission of HIV-1, and disease progression
    Bailey, AJ
    Newell, ML
    De Rossi, A
    Giaquinto, C
    Iasci, A
    Ravizza, M
    Garcia-Rodriguez, MC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 211 - 212
  • [47] High Levels of CC-Chemokine Expression and Downregulated Levels of CCR5 During HIV-1/HTLV-1 and HIV-1/HTLV-2 Coinfections
    Oo, Z.
    Barrios, C. S.
    Castillo, L.
    Beilke, M. A.
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (05) : 790 - 797
  • [48] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
  • [49] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [50] An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
    Sterjovski, Jasminka
    Roche, Michael
    Churchill, Melissa J.
    Ellett, Anne
    Farrugia, William
    Gray, Lachlan R.
    Cowley, Daniel
    Poumbourios, Pantelis
    Lee, Benhur
    Wesselingh, Steven L.
    Cunningham, Anthony L.
    Ramsland, Paul A.
    Gorry, Paul R.
    VIROLOGY, 2010, 404 (02) : 269 - 278